We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Read MoreHide Full Article
In the latest close session, Eli Lilly (LLY - Free Report) was up +1.99% at $1,137.86. This move outpaced the S&P 500's daily loss of 0.48%. Meanwhile, the Dow experienced a drop of 0.29%, and the technology-dominated Nasdaq saw a decrease of 0.56%.
Shares of the drugmaker have depreciated by 5.46% over the course of the past month, underperforming the Medical sector's loss of 2.01%, and the S&P 500's loss of 0.82%.
Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2026. The company's upcoming EPS is projected at $9.56, signifying a 36.18% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $22.08 billion, showing a 25.46% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $36.09 per share and revenue of $88.83 billion, indicating changes of +49.07% and +36.28%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.49% higher. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
Investors should also note Eli Lilly's current valuation metrics, including its Forward P/E ratio of 30.92. This valuation marks a premium compared to its industry average Forward P/E of 15.51.
It's also important to note that LLY currently trades at a PEG ratio of 1.39. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.98 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Why the Market Dipped But Eli Lilly (LLY) Gained Today
In the latest close session, Eli Lilly (LLY - Free Report) was up +1.99% at $1,137.86. This move outpaced the S&P 500's daily loss of 0.48%. Meanwhile, the Dow experienced a drop of 0.29%, and the technology-dominated Nasdaq saw a decrease of 0.56%.
Shares of the drugmaker have depreciated by 5.46% over the course of the past month, underperforming the Medical sector's loss of 2.01%, and the S&P 500's loss of 0.82%.
Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2026. The company's upcoming EPS is projected at $9.56, signifying a 36.18% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $22.08 billion, showing a 25.46% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $36.09 per share and revenue of $88.83 billion, indicating changes of +49.07% and +36.28%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.49% higher. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
Investors should also note Eli Lilly's current valuation metrics, including its Forward P/E ratio of 30.92. This valuation marks a premium compared to its industry average Forward P/E of 15.51.
It's also important to note that LLY currently trades at a PEG ratio of 1.39. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.98 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.